← Leaderboards
Kenneth I Ataga
University Of North Carolina Chapel Hill
$8,201,532
Attributed
$15,522,984
Total exposure
32
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,522,988 · 31
FDA$1,999,996 · 1
By mechanism
R01$8,337,789 · 4
U01$6,086,709 · 1
K23$625,760 · 1
R21$346,670 · 1
M01$126,056 · 25
Top collaborators
- David R Archer5 shared
- Santosh Saraf5 shared
- Nigel S Key4 shared
- Nigel Mackman4 shared
- Rafal L Pawlinski4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Rupa C Redding-Lallinger$303,888
- James E Faber$12,717,060
- Kim L Brouwer$15,343,248
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaSickle CellResearch PersonnelResourcesSourceUnited States National Institutes Of HealthFundingGrantComputer Retrieval Of Information On Scientific Projects DatabaseInstitutionFunctional DisorderPathogenesisSafetyPulmonary HypertensionOrganHydroxyureaClinical TrialsLeadAlbuminuriaIschemic StrokeChronic Kidney FailureReportingKidneyCoagulation Process
Grant awards (56)
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)$610,088
R01 · FY2025 · HL · contact PI
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)$606,572
R01 · FY2024 · HL · contact PI
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)$626,209
R01 · FY2023 · HL · contact PI
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)$645,294
R01 · FY2022 · HL · contact PI
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)$705,287
R01 · FY2021 · HL · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$399,998
R01 · FY2021 · FD · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$399,999
R01 · FY2020 · FD · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$399,999
R01 · FY2019 · FD · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$400,000
R01 · FY2018 · FD · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$233,900
R01 · FY2017 · FD · contact PI
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIA$166,100
R01 · FY2017 · FD · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,481,743
U01 · FY2016 · HL · contact PI
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$474,581
R01 · FY2016 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,459,516
U01 · FY2015 · HL · contact PI
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$450,727
R01 · FY2015 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,452,109
U01 · FY2014 · HL · contact PI
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$450,555
R01 · FY2014 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,693,341
U01 · FY2013 · HL · contact PI
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$438,932
R01 · FY2013 · HL · contact PI
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy$504,596
R01 · FY2012 · HL · contact PI
COAGULATION ACTIVATION IN SICKLE CELL DISEASE$417,566
R01 · FY2010 · HL · contact PI
COAGULATION ACTIVATION IN SICKLE CELL DISEASE$407,386
R01 · FY2009 · HL · contact PI
Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease$157,335
R21 · FY2009 · HL · contact PI
Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease$189,335
R21 · FY2008 · HL · contact PI
PREVALENCE OF PULMONARY HYPERTENSION IN SICKLE CELL DISEASE$2,449
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: LONGTERM SAFETY OF ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICK$1,454
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE III, ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL$1,377
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ARGININE SUPPLEMENTATION IN SICKLE CELL ANEMIA: PHYSIOLOGICAL A$1,071
M01 · FY2008 · RR · contact PI
6R-BH4 IN SUBJECTS WITH SICKLE CELL DISEASE$842
M01 · FY2008 · RR · contact PI
EFFECT OF HYDROXYUREA ON BLOOD COAGULATION IN PATIENT WITH SICKLE CELL DISEASE$459
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: BOSENTAN IN SICKLE CELL PATIENTS WITH SYMPTOMATIC PULMONARY HYPE$230
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: BOSENTAN IN PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION & S$230
M01 · FY2008 · RR · contact PI
PULMONARY HYPERTENSION IN SICKLE CELL DISEASE WITH IDENTIFICATION OF CLINICAL AS$76
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMPACTS TRIAL: INVESTIGATION OF THE MODULATION OF PHOSPHOLIPASE$76
M01 · FY2008 · RR · contact PI
PHASE III, ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL DISEASE$16,319
M01 · FY2007 · RR · contact PI
PREVALENCE OF PULMONARY HYPERTENSION IN SICKLE CELL DISEASE$5,440
M01 · FY2007 · RR · contact PI
ARGININE SUPPLEMENTATION IN SICKLE CELL ANEMIA: PHYSIOLOGICAL AND PROPHYLACTIC$3,189
M01 · FY2007 · RR · contact PI
EFFECT OF HYDROXYUREA ON BLOOD COAGULATION IN PATIENT WITH SICKLE CELL DISEASE$1,688
M01 · FY2007 · RR · contact PI
LONGTERM SAFETY OF ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL PATIENTS$1,313
M01 · FY2007 · RR · contact PI
BOSENTAN IN PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION & SICKLE CELL$375
M01 · FY2007 · RR · contact PI
BOSENTAN IN SICKLE CELL PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION$187
M01 · FY2007 · RR · contact PI
DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE$125,152
K23 · FY2006 · RR · contact PI
THE EFFECT OF ANTICOAGULATION IN SICKLE CELL ANEMIA$14,372
M01 · FY2006 · RR · contact PI
PREVALENCE OF PULMONARY HYPERTENSION IN SICKLE CELL DISEASE$12,142
M01 · FY2006 · RR · contact PI
PHASE III, ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL DISEASE$7,186
M01 · FY2006 · RR · contact PI
ARGININE SUPPLEMENTATION IN SICKLE CELL ANEMIA: PHYSIOLOGICAL AND PROPHYLACTIC$6,195
M01 · FY2006 · RR · contact PI
EFFECT OF HYDROXYUREA ON BLOOD COAGULATION IN PATIENT WITH SICKLE CELL DISEASE$4,460
M01 · FY2006 · RR · contact PI
DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE$125,152
K23 · FY2005 · RR
THE EFFECT OF ANTICOAGULATION IN SICKLE CELL ANEMIA$26,389
M01 · FY2005 · RR
PREVALENCE OF PULMONARY HYPERTENSION IN SICKLE CELL DISEASE$11,310
M01 · FY2005 · RR
ARGININE SUPPLEMENTATION IN SICKLE CELL ANEMIA: PHYSIOLOGICAL AND PROPHYLACTIC$3,141
M01 · FY2005 · RR
EFFECT OF HYDROXYUREA ON BLOOD COAGULATION IN PATIENT WITH SICKLE CELL DISEASE$1,256
M01 · FY2005 · RR
DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE$125,152
K23 · FY2004 · RR
Prevalence of Pulmonary Hypertension in Sickle Cell Disease$2,830
M01 · FY2004 · RR
DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE$125,152
K23 · FY2003 · RR
DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE$125,152
K23 · FY2002 · RR